

Giulio Metro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4779179/publications.pdf>

Version: 2024-02-01

202
papers

3,942
citations

117625

34
h-index

175258

52
g-index

206
all docs

206
docs citations

206
times ranked

5727
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 479-485.	2.5	253
2	Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. <i>Annals of Oncology</i> , 2011, 22, 625-630.	1.2	146
3	Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. <i>Medical Oncology</i> , 2016, 33, 18.	2.5	129
4	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1.	2.6	118
5	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. <i>Annals of Oncology</i> , 2006, 17, 1120-1127.	1.2	93
6	CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. <i>Journal of Thoracic Oncology</i> , 2015, 10, e26-e27.	1.1	93
7	HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. <i>Clinical Cancer Research</i> , 2011, 17, 2055-2064.	7.0	92
8	Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 10.	8.6	89
9	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 264.	2.8	87
10	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
11	Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. <i>Lung Cancer</i> , 2012, 78, 81-86.	2.0	68
12	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	4.2	60
13	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 53-68.	2.5	56
14	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. <i>Tumori</i> , 2017, 103, 405-421.	1.1	52
15	Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 543-553.	5.1	52
16	Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2014, 23, 79-91.	7.1	51
17	Clinical experience with gefitinib: An update. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 31-45.	4.4	50
18	Future options for ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 211-219.	2.0	50

#	ARTICLE	IF	CITATIONS
19	Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. <i>Breast</i> , 2008, 17, 499-505.	2.2	47
20	Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. <i>Medical Oncology</i> , 2017, 34, 105.	2.5	47
21	Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. <i>Journal of Clinical Medicine</i> , 2020, 9, 1047.	2.4	47
22	Advances on EGFR mutation for lung cancer. <i>Translational Lung Cancer Research</i> , 2012, 1, 5-13.	2.8	46
23	Supportive care in neurooncology. <i>Current Opinion in Oncology</i> , 2010, 22, 621-626.	2.4	45
24	Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 1-13.	0.8	44
25	The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 673-682.	2.4	44
26	Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. <i>Clinical Lung Cancer</i> , 2015, 16, e223-e228.	2.6	44
27	HER-2-positive metastatic breast cancer: trastuzumab and beyond. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2583-2601.	1.8	43
28	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. <i>Lung Cancer</i> , 2015, 90, 255-260.	2.0	43
29	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. <i>Translational Lung Cancer Research</i> , 2020, 9, 1533-1542.	2.8	43
30	ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3003-3014.	2.4	42
31	Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. <i>Clinical Lung Cancer</i> , 2014, 15, 86-92.	2.6	40
32	Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 401-411.	7.7	40
33	Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 717-725.	2.3	39
34	Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis. <i>Oncotarget</i> , 2016, 7, 30561-30574.	1.8	37
35	Safety and Efficacy of Nivolumab in Patients With Advanced Non-Small-Cell Lung Cancer Treated Beyond Progression. <i>Clinical Lung Cancer</i> , 2019, 20, 178-185.e2.	2.6	35
36	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	4.5	35

#	ARTICLE	IF	CITATIONS
37	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4972-4981.	1.4	35
38	Clinical Utility of Continuing Trastuzumab Beyond Brain Progression in HER2-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2007, 12, 1467-1469.	3.7	34
39	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). <i>Translational Lung Cancer Research</i> , 2019, 8, 1163-1173.	2.8	34
40	Optimal management of ALK -positive NSCLC progressing on crizotinib. <i>Lung Cancer</i> , 2017, 106, 58-66.	2.0	33
41	Non-coding RNAs in lung cancer. <i>Oncoscience</i> , 2014, 1, 674-705.	2.2	33
42	Treatment of advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2006, 17, ii36-ii41.	1.2	31
43	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1436-1441.	1.2	31
44	Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab. <i>Acta Oncologica</i> , 2020, 59, 1058-1063.	1.8	31
45	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 387-404.	3.2	30
46	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021, 12, 880-889.	1.9	30
47	Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies. <i>Oncology</i> , 2010, 78, 141-149.	1.9	29
48	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. <i>Medical Oncology</i> , 2018, 35, 72.	2.5	29
49	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. <i>Annals of Oncology</i> , 2006, 17, ii42-ii45.	1.2	28
50	Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. <i>BMC Cancer</i> , 2009, 9, 101.	2.6	28
51	Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool. <i>Frontiers in Immunology</i> , 2020, 11, 839.	4.8	28
52	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 391-397.	2.3	27
53	Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. <i>Clinical Drug Investigation</i> , 2016, 36, 683-686.	2.2	27
54	Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 159-168.	2.8	27

#	ARTICLE	IF	CITATIONS
55	Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. <i>Anticancer Research</i> , 2009, 29, 2607-10.	1.1	26
56	Alectinib™s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. <i>Journal of Neuro-Oncology</i> , 2016, 129, 355-361.	2.9	25
57	Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. <i>Genes</i> , 2021, 12, 679.	2.4	25
58	Large Cell Neuroendocrine Carcinoma Transformation and EGFR -T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1304-1311.	3.0	24
59	Osimertinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 257-276.	1.8	24
60	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	2.8	24
61	<i>In Situ</i> Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy. <i>Cancer Investigation</i> , 2009, 28, 172-180.	1.3	23
62	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2601-2613.	1.8	22
63	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 3337.	3.7	21
64	Emerging drugs for small-cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 591-606.	2.4	20
65	Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. <i>BMC Cancer</i> , 2012, 12, 482.	2.6	20
66	Emerging drugs for small cell lung cancer – an update. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 31-36.	2.4	20
67	Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1299.	2.8	20
68	Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1405-1412.	2.3	19
69	Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2013, 9, 167-177.	2.4	19
70	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. <i>Lung Cancer</i> , 2016, 95, 82-87.	2.0	19
71	The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2020, 21, e539-e543.	2.6	19
72	Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3041-3053.	4.2	19

#	ARTICLE	IF	CITATIONS
73	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	2.8	19
74	Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression $\geq 50\%$. <i>Journal of Immunotherapy</i> , 2020, 43, 299-306.	2.4	18
75	Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. <i>Journal of Neuro-Oncology</i> , 2010, 100, 209-215.	2.9	17
76	Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?. <i>Lung Cancer Management</i> , 2019, 8, LMT18.	1.5	17
77	Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. <i>Lung Cancer</i> , 2021, 152, 127-134.	2.0	17
78	RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature. <i>Oncology and Therapy</i> , 2020, 8, 333-339.	2.6	16
79	Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation. <i>Journal of Thoracic Oncology</i> , 2018, 13, e145-e147.	1.1	15
80	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. <i>Clinical Lung Cancer</i> , 2021, 22, e180-e192.	2.6	15
81	Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. <i>Journal of Breast Cancer</i> , 2016, 19, 324.	1.9	14
82	CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 284-290.	2.0	14
83	Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. <i>Clinical Drug Investigation</i> , 2018, 38, 983-987.	2.2	14
84	High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. <i>Genes</i> , 2021, 12, 273.	2.4	14
85	Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. <i>Journal of Neuro-Oncology</i> , 2008, 87, 79-84.	2.9	13
86	Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series. <i>Clinical Lung Cancer</i> , 2014, 15, 470-474.	2.6	13
87	Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 25, 856-861.	1.1	13
88	New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 145.	5.2	13
89	Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	12
90	miRNAs and resistance to EGFR TKIs in EGFR-mutant non-small cell lung cancer: beyond traditional mechanisms of resistance. <i>Ecancermedicalscience</i> , 2015, 9, 569.	1.1	12

#	ARTICLE	IF	CITATIONS
91	Fatal acute disseminated intravascular coagulation as presentation of advanced ALK -positive non-small cell lung cancer: Does oncogene addiction matter?. <i>Thrombosis Research</i> , 2018, 163, 51-53.	1.7	12
92	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. <i>Lung Cancer</i> , 2019, 134, 210-217.	2.0	12
93	Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 965-980.	2.8	12
94	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3713-3736.	2.8	12
95	Development of gemcitabine in non-small cell lung cancer: the Italian contribution. <i>Annals of Oncology</i> , 2006, 17, v37-v46.	1.2	11
96	Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. <i>Supportive Care in Cancer</i> , 2008, 16, 1375-1380.	2.2	11
97	Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. <i>Ecancermedicalsecience</i> , 2015, 9, 559.	1.1	11
98	Upfront pembrolizumab as an effective treatment start in patients with PD-L1â€‰â‰¥â€‰50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis. <i>Clinical and Translational Oncology</i> , 2021, 23, 1818-1826.	2.4	11
99	Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNA Clamp, and Digital PCR. <i>Diagnostics</i> , 2020, 10, 1062.	2.6	10
100	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9036-9036.	1.6	10
101	Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-9.	1.5	9
102	Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3890-S3894.	1.4	9
103	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019, 105, 3-14.	1.1	9
104	Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. <i>Anticancer Research</i> , 2008, 28, 1245-58.	1.1	9
105	Time to First Tumor Progression as Outcome Predictor of a Second Trastuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer. <i>Breast Journal</i> , 2010, 16, 66-72.	1.0	8
106	Phase Iâ€‰II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 687-693.	2.3	8
107	The safety of nivolumab for the treatment of advanced non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 101-109.	2.4	8
108	Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e9-e12.	1.1	8

#	ARTICLE	IF	CITATIONS
109	Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 4064-4069.	1.4	7
110	EGFR targeted therapy for lung cancer: are we almost there?. <i>Translational Lung Cancer Research</i> , 2018, 7, S142-S145.	2.8	7
111	KRAS mutation and DNA repair and synthesis genes in non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 689-696.	1.0	7
112	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	1.9	7
113	Malignant Giant Solitary Fibrous Tumor of the Pleura Metastatic to the Thyroid Gland. <i>Tumori</i> , 2016, 102, S16-S21.	1.1	6
114	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 708-716.	2.4	6
115	Supportive Care: Low Cost, High Value. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 240-250.	3.8	6
116	New Target Therapies for Brain Metastases from Breast Cancer. <i>Current Cancer Drug Targets</i> , 2012, 12, 210-217.	1.6	6
117	Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2834-2835.	1.6	5
118	Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. <i>Lung Cancer</i> , 2018, 120, 70-74.	2.0	5
119	Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e220-e222.	1.1	5
120	Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2972-2980.	3.3	5
121	Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. <i>Genes</i> , 2021, 12, 992.	2.4	5
122	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	17.0	5
123	Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	5
124	Aromatase inhibitors in post-menopausal metastatic breast carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1023-1036.	4.1	4
125	New targeted therapies for non-small-cell lung cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 335-350.	0.2	4
126	MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Thoracic Oncology</i> , 2018, 13, S390-S391.	1.1	4

#	ARTICLE	IF	CITATIONS
127	Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1 >50%.. Journal of Clinical Oncology, 2020, 38, e21651-e21651.	1.6	4
128	COX-2 targeting in cancer: a new beginning?. Annals of Oncology, 2008, 19, 1209-1210.	1.2	3
129	Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received: a single institution analysis. Annals of Oncology, 2015, 26, vi78.	1.2	3
130	Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2017, 12, e51-e55.	1.1	3
131	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Future Oncology, 2018, 14, 353-361.	2.4	3
132	Phase II study of weekly carboplatin in pretreated adult malignant gliomas. Journal of Neuro-Oncology, 2019, 144, 211-216.	2.9	3
133	Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review. Oncology and Therapy, 2020, 8, 341-350.	2.6	3
134	Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC). Journal of Clinical Oncology, 2007, 25, 1066-1066.	1.6	3
135	First-line alectinib for ALK-positive lung cancer: is there room for further improvement?. Drugs in Context, 2018, 7, 1-6.	2.2	3
136	Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NEXUS' linking an unsuccessful treatment and a potentially active one?. Journal of Thoracic Disease, 2012, 4, 635-8.	1.4	3
137	Letter to the editor concerning Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA™. Annals of Oncology, 2015, 26, 1033-1034.	1.2	2
138	How might treatment of ALK-positive non-small cell lung cancer change in the near future?. Expert Review of Anticancer Therapy, 2016, 16, 997-999.	2.4	2
139	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. Translational Lung Cancer Research, 2018, 7, S294-S296.	2.8	2
140	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. Translational Lung Cancer Research, 2018, 7, S290-S293.	2.8	2
141	Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS). Annals of Oncology, 2019, 30, v624.	1.2	2
142	1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer. Annals of Oncology, 2020, 31, S825-S826.	1.2	2
143	Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. Clinical Lung Cancer, 2020, 21, e478-e487.	2.6	2
144	Changes in HER2 overexpression between primary tumor and autologous metastases: Correlations with clinical and biological features. Journal of Clinical Oncology, 2008, 26, 11071-11071.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.. Journal of Clinical Oncology, 2018, 36, 9084-9084.	1.6	2
146	Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2022, 14, 816-819.	1.4	2
147	PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm. Translational Lung Cancer Research, 2021, 10, 4617-4630.	2.8	2
148	Clinical Impact of Presence and Type of Kras Mutation in a Population of EGFR Wild Type (WT) Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (PTS) Treated with Platinum-Based Chemotherapy: A Retrospective Analysis. Annals of Oncology, 2012, 23, ix427.	1.2	1
149	Sequential strategy with ALK-TKIs for ALK-positive advanced NSCLC: results of a multicenter analysis. Annals of Oncology, 2015, 26, vi75.	1.2	1
150	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Management, 2016, 5, 79-90.	1.5	1
151	Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?. Journal of Radiation Oncology, 2017, 6, 11-19.	0.7	1
152	Targeted therapy for patients with ALK positive NSCLC: Results from the transalpine cohort. Annals of Oncology, 2017, 28, ii9.	1.2	1
153	MAO2.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC. Journal of Thoracic Oncology, 2018, 13, S358-S359.	1.1	1
154	Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial. Annals of Oncology, 2019, 30, ii48-ii49.	1.2	1
155	Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option. Translational Lung Cancer Research, 2019, 8, S378-S382.	2.8	1
156	Interim analysis from a phase IIIB, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC. Annals of Oncology, 2019, 30, ix161-ix162.	1.2	1
157	P1.16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort. Journal of Thoracic Oncology, 2019, 14, S589.	1.1	1
158	Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER2-positive metastatic breast cancer. Journal of Clinical Oncology, 2008, 26, 1071-1071.	1.6	1
159	Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC).. Journal of Clinical Oncology, 2010, 28, 1155-1155.	1.6	1
160	Correlation of circulating miRNA levels with progression-free survival (PFS) and overall survival (OS) in early-stage lung adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 11099-11099.	1.6	1
161	Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.. Journal of Clinical Oncology, 2014, 32, 7600-7600.	1.6	1
162	Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2010, 28, 1059-1059.	1.6	1

#	ARTICLE	IF	CITATIONS
163	Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer"; Translational Lung Cancer Research, 2016, 5, 561-562.	2.8	1
164	Immune gene expression and bayesian network analysis in advanced non small cell lung cancer (NSCLC) patients treated with immunotherapy.. Journal of Clinical Oncology, 2019, 37, e20693-e20693.	1.6	1
165	Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. Oncology and Therapy, 2022, 10, 291-300.	2.6	1
166	Sacrum colon-rectal cancer metastasis: microwave ablation for palliative pain treatment. Recenti Progressi in Medicina, 2016, 107, 673-676.	0.8	1
167	2509 POSTER Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM): preliminary results. European Journal of Cancer, Supplement, 2007, 5, 230.	2.2	0
168	Efficacy of the Irreversible EGFR-HER2 Dual Inhibitor Afatinib in Pretreated Lung Adenocarcinoma. Annals of Oncology, 2012, 23, ix423.	1.2	0
169	Targeting angiogenesis in advanced non-small-cell lung cancer: are biomarkers needed?. Current Respiratory Care Reports, 2013, 2, 72-78.	0.6	0
170	P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice. Journal of Thoracic Oncology, 2017, 12, S706-S707.	1.1	0
171	P3.02b-008 Quantification and Monitoring of Treatment Response in EGFR Mutant NSCLC Patients by Digital-PCR in Plasma cftDNA. Journal of Thoracic Oncology, 2017, 12, S1189-S1190.	1.1	0
172	P3.02c-068 Immunotherapy against Non-Small Cell Lung Cancer (NSCLC): Looking for Predictive Factors to Avoid an Untargeted Shooting. Journal of Thoracic Oncology, 2017, 12, S1317-S1318.	1.1	0
173	MA04.06 Signaling Networks in KRAS-Mutant Advanced NSCLC: A Complex Landscape Involving Immunoresponse, Inflammation and DNA Repair. Journal of Thoracic Oncology, 2017, 12, S360-S361.	1.1	0
174	ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort. Annals of Oncology, 2017, 28, vi54.	1.2	0
175	Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels. Annals of Oncology, 2017, 28, vi58-vi59.	1.2	0
176	Efficacy of ceritinib in a "real-world" population of crizotinib-refractory ALK-positive NSCLCs: Results of the Italian compassionate use program. Annals of Oncology, 2017, 28, ii38.	1.2	0
177	Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program. Annals of Oncology, 2017, 28, vi56-vi57.	1.2	0
178	Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. International Journal of Biological Markers, 2018, 33, 549-550.	1.8	0
179	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC) - European subset. Annals of Oncology, 2018, 29, viii528.	1.2	0
180	P1.01-73 Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung Cancer) Trial: An Italian Experience. Journal of Thoracic Oncology, 2018, 13, S490-S491.	1.1	0

#	ARTICLE	IF	CITATIONS
181	27P ALK immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, S14-S15.	1.1	0
182	Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study. <i>Annals of Oncology</i> , 2019, 30, v598-v599.	1.2	0
183	Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest. <i>Annals of Oncology</i> , 2019, 30, v622-v623.	1.2	0
184	Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis. <i>Annals of Oncology</i> , 2019, 30, ii57.	1.2	0
185	P2.14-58 A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, S853-S854.	1.1	0
186	P2.04-84 NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, S742-S743.	1.1	0
187	P1.01-65 Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, S384-S385.	1.1	0
188	Baseline neutrophil-to-lymphocyte ratio and PD-L1 expression level or LDH value may predict outcome of patients with high PD-L1 advanced non-small cell lung cancer treated with first-line pembrolizumab. <i>Lung Cancer</i> , 2020, 139, S58-S59.	2.0	0
189	Fixed dose rate (FDR) gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM): Preliminary results of a phase II study. <i>Journal of Clinical Oncology</i> , 2007, 25, 12502-12502.	1.6	0
190	Trastuzumab-related cardiotoxicity in setting outside clinical trials: A mono-institutional experience. <i>Journal of Clinical Oncology</i> , 2008, 26, 22116-22116.	1.6	0
191	EGFR Gene Copy Number and Response to Lapatinib/Capecitabine in HER2 Positive Metastatic Breast Cancer Patients Pretreated with Trastuzumab.. , 2009, , .		0
192	Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience.. <i>Journal of Clinical Oncology</i> , 2010, 28, 1108-1108.	1.6	0
193	Glioblastoma Patients: Role of Methylated MGMT. , 2011, , 73-79.		0
194	Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2011, 29, e11027-e11027.	1.6	0
195	Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.. <i>Journal of Clinical Oncology</i> , 2011, 29, 568-568.	1.6	0
196	Clinical outcome of KRAS-mutated advanced non-small cell lung cancer (NSCLC) patients (pts): A mono-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2011, 29, 7580-7580.	1.6	0
197	Targeted Therapies for Non-small-Cell Lung Cancer. , 2012, , 93-114.		0
198	Do "pan-negative" never-smoker (NS) lung cancer patients (pts) represent a new distinct subgroup? Data from a single-institution experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19054-e19054.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Clinical features and outcome in never-smoker (NS) non-small cell lung cancer (NSCLC) patients (pts): A single-institution observational analysis.. Journal of Clinical Oncology, 2014, 32, e22152-e22152.	1.6	0
200	Programmed cell death ligand 1(PD-L1), Programmed death 1+(PD-1) lymphocytes and Tumor infiltrating lymphocytes (TILs): are they playing a role in predicting response to anti-PD-1 therapies?. Journal of Clinical Oncology, 2016, 34, e20652-e20652.	1.6	0
201	Quantification and monitoring of treatment response in <i>EGFR</i> mutant non-small cell lung cancer patients using Digital PCR and Therascreen in plasma cell-free tumour DNA.. Journal of Clinical Oncology, 2016, 34, e23037-e23037.	1.6	0
202	Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: A systematic review and literature-based meta-analysis.. Journal of Clinical Oncology, 2019, 37, e20565-e20565.	1.6	0